2023年5月17日

文士和盛行的伴侶CRISPR-based遺傳藥物根據協議,獲勝取得專有權使用抄寫員的CRISPR X-Editing技術開發藥物。文士和流行開發基因治療嚴重的神經和神經肌肉疾病。文士治療已經進入了一個與禮來公司和公司戰略合作子公司盛行加速體內CRISPR-based療法的治療目標嚴重的神經和神經肌肉疾病的原因。根據協議,獲勝取得專有權使用抄寫員的CRISPR X-Editing (XE)技術開發藥物。這筆交易將會看到文士的新CRISPR的集成設計方法和獲勝的經驗在發展中為特定的基因遺傳的神經係統疾病藥物的目標。抄寫員將獲得75美元,包括預付款和通過可轉換股權投資。該公司還開發和商業裏程碑支付超過15億美元。獲勝將支付研究經費和分層版稅淨未來銷量,而抄寫員將有權選擇共同出資並分享利潤在美國一個合作計劃從最新的夥伴關係。文士療法CEO本傑明奧克斯說:“引人注目的體內生成概念驗證數據在多個疾病領域,抄寫員驗證我們X-Editing技術行業領先的編輯活動,特異性和產能。“我們的目標是更廣泛的支持療法,幫助人們生活在這些條件。” The platform based on Scribe CRISPR by Design applies holistic engineering to convert bacterial immune systems into key genome editing technologies targeting the patients’ specific requirements. The company’s in vivo genome editing tools directly modify genes in the body and provide multiple benefits in safety, efficacy and delivery over currently available methods. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy Share this article